1. India Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Transgene Biotek Limited.

Transgene Biotek Limited.

BBSE:TRABI
2.37
INR
-0.07
(-2.87%)
-0.21EPS
234.89MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.13
0.04
0.02
0.01
- -
0.01
- -
0.02
0.01
0.01
0.03
0.03
0.03
0.03
Basic EPS, GAAP
-17.61
-2.53
-2.84
-2.62
-0.85
-1.16
-1.45
-1.38
-1.37
-0.79
-0.09
-0.09
-0.22
-0.21
Free Cash Flow per Basic Share
-0.28
0.47
0.85
- -
-0.08
-0.23
0.02
- -
0.01
- -
- -
0.16
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
27.18
25.26
23.02
7.77
6.92
5.76
4.31
2.94
2.29
1.5
1.41
1.32
1.11
- -
Tangible Book Value per Share
4.11
4.37
0.66
-0.12
0.29
0.4
0.24
0.14
0.79
0.63
0.55
0.46
0.24
- -
Basic Weighted Avg Shares
76
76
76
76
76
76
76
76
76
76
76
75
75
77
Sales/Revenue/Turnover
10
3
2
1
- -
1
- -
2
1
1
2
3
2
2
Operating Margin (%)
-1,859.32
-5,968.78
-11,916.81
-25,393.95
- -
-14,477.56
- -
-5,994.44
-11,734.14
-9,769.69
-219.54
-466.63
-351.61
-294.86
Depreciation Expense
172
172
205
175
99
99
99
99
99
50
1
1
2
2
Net Income, GAAP
-1,334
-191
-215
-199
-64
-88
-110
-104
-104
-60
-7
-7
-17
-16
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-13,597.71
-6,079.27
-11,864.37
-28,699.24
- -
-12,334.25
- -
-6,154.34
-11,998.4
-10,904.9
-279.05
-259.34
-782.62
-725.07
Working Capital
-53
-70
-79
-110
-130
-119
-130
-135
-85
-94
-100
-115
-122
- -
LT Debt
59
63
48
52
38
41
43
45
48
50
51
61
68
- -
Total Equity
2,060
1,914
1,744
589
524
436
327
222
174
114
107
100
84
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-50.54
-9.63
-11.78
-17.03
-11.57
-18.31
-28.73
-38
-52.51
-41.8
-5.94
-6.52
-17.96
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
103
- -
LT Borrowings
- -
68
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
76
76
Market Capitalization
239
150
235

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
10
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
133
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
103
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-23.61%
-17.01%
-16.48%
Free Cash Flow
2,564.6%
5,714.62%
-100.94%
Net Income, GAAP
-0.3%
3.2%
144.48%
Sales/Revenue/Turnover
- -
46.6%
-18.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
1
1
1
3
2026
- -
1
1
1
2
2027
1
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.03
-0.01
-0.01
-0.09
-0.09
2026
-0.06
-0.05
-0.05
-0.06
-0.22
2027
-0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
K. Koteswara Rao
Full Time Employees
8
Sector
Health technology
Industry
Biotechnology
Address
Plot No. 69 & 70 Hyderabad TS India 502325
IPO Date
Sep 23, 1992
Website
transgenebiotek.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Transgene Biotek Limited is an Indian biotechnology company engaged in the research, development, manufacture, and commercialization of various biopharmaceutical products and medical reagents. Founded in 1990 and headquartered in Hyderabad, India, the company operates primarily in the pharmaceuticals and biotech sectors focusing on oncology, auto-immunity, drug delivery, and biogenerics. Its main product offerings include oral formulations of proteins and peptides utilizing proprietary TrabiORAL technology; biogeneric molecules for disease diagnosis; immuno-diagnostic reagents; pharmaceutical capsules including branded products like Trabidha Plus 200 Capsule; and other chemical and immuno-diagnostic reagents for qualitative and quantitative biochemical estimations. Transgene Biotek's products are marketed in multiple countries including Africa, Russia, China, Malaysia, and the Philippines. In recent years, the company has initiated manufacturing operations at its own facilities with a capacity expansion plan targeting bulk drug production primarily for the Asia-Pacific and Latin American markets, while exploring regulatory approvals and partnerships to enter the European and U.S. markets. The company is actively pursuing strategic alliances and has engaged in technology transfer agreements for monetizing several of its developed products. It has also been involved in discussions about acquisitions to enhance its product portfolio and geographic reach, with a focus on commercialization of novel therapies. Recent major changes include the commencement of manufacturing at a new 4 kiloliter capacity facility along with plans for an additional 64 kiloliter API manufacturing unit, ongoing clinical trials advancing its drug candidates, and active efforts to expand into regulated international markets through partnerships and collaborations. Transgene Biotek remains focused on innovation in oral and nasal drug delivery systems, bringing new formulations to market with significant potential to improve patient outcomes in areas of unmet medical need. The company is listed on the Bombay Stock Exchange under the ticker TRABI and continues to evolve its pipeline and operational capabilities in the biotechnology industry.